Full Name
Yong, W.-P.
Yong, W.P.
Peng, Y.W.


Results 1-20 of 38 (Search time: 0.008 seconds).

Issue DateTitleAuthor(s)
1May-2012A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targetsDeng, N. ; Goh, L.K. ; Wang, H.; Das, K. ; Tao, J.; Tan, I.B.; Zhang, S.; Lee, M.; Wu, J.; Lim, K.H.; Lei, Z.; Goh, G.; Lim, Q.-Y.; Tan, A.L.-K.; Poh, D.Y.S.; Riahi, S.; Bell, S.; Shi, M.M.; Linnartz, R.; Zhu, F.; Yeoh, K.G.; Toh, H.C.; Yong, W.P. ; Cheong, H.C.; Rha, S.Y.; Boussioutas, A.; Grabsch, H.; Rozen, S. ; Tan, P. 
2Jul-2006A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancerSoo, R.A. ; Wang, L.Z. ; Tham, L.S.; Yong, W.P. ; Boyer, M.; Lim, H.L.; Lee, H.S.; Millward, M.; Liang, S.; Beale, P.; Lee, S.C. ; Goh, B.C.
3Jul-2008A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancersYong, W.-P. ; Wang, L.-Z. ; Tham, L.-S.; Wong, C.-I.; Lee, S.-C. ; Soo, R. ; Sukri, N.; Lee, H.-S.; Goh, B.-C.
410-Jun-2012Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trialVan Cutsem, E.; De Haas, S.; Kang, Y.-K.; Ohtsu, A.; Tebbutt, N.C.; Xu, J.M.; Yong, W.P. ; Langer, B.; Delmar, P.; Scherer, S.J.; Shah, M.A.
5Dec-2012Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer CenterKoomanan, N.; Ko, Y. ; Yong, W.-P. ; Ng, R.; Wong, Y.-P.; Lim, S.-W. ; Salim, A. ; Chan, A. 
6May-2009Clinical pharmacology and pharmacogenetics of gemcitabineWong, A.; Soo, R.A. ; Yong, W.-P. ; Innocenti, F.
74-Dec-2012Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 ExpressionWong, F.Y.; Liem, N.; Xie, C.; Yan, F.L.; Wong, W.C.; Wang, L. ; Yong, W.-P. 
821-May-2010Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular featuresAng, P.W.; Loh, M. ; Liem, N.; Lim, P.L.; Grieu, F.; Vaithilingam, A.; Platell, C.; Yong, W.P. ; Iacopetta, B.; Soong, R. 
913-Mar-2014Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancerGoh, L.K.; Liem, N.; Vijayaraghavan, A.; Chen, G.; Lim, P.L.; Tay, K.-J.; Chang, M.; Low, J.S.W.; Joshi, A.; Huang, H.H.; Kalaw, E.; Tan, P.H.; Hsieh, W.-S.; Yong, W.P. ; Alumkal, J.; Sim, H.G.
1028-Mar-2014DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: A comprehensive profiling approachLoh, M.; Liem, N.; Vaithilingam, A.; Lim, P.L.; Sapari, N.S.; Elahi, E.; Mok, Z.Y.; Cheng, C.L.; Yan, B.; Pang, B.; Salto-Tellez, M. ; Yong, W.P. ; Iacopetta, B.; Soong, R.
11Mar-2013Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group StudyPeveling-Oberhag, J.; Zeuzem, S.; Yong, W.P. ; Kunz, T.; Paquet, T.; Bouillaud, E.; Urva, S.; Anak, O.; Sellami, D.; Kobalava, Z.
1213-Jun-2016Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive reviewNicholas Li-Xun Syn; Wei-Peng Yong ; Boon-Cher Goh ; Soo-Chin Lee 
132019FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling PathwayYeo; Subhash; KAZUTO SUDA ; HAYRI EMRAH BALCIOGLU ; ZHOU SIQIN ; THUYA WIN LWIN ; LOH XIN YI ; Jammula; PRAVEEN CHAKRAVARTHY PEETHALA ; Tan; Xie; Wong; Ladoux,Benoit ; Ito; YANG HE ; Goh; Wang; YONG WEI PENG 
14Sep-2011Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patientsWong, A.L.-A.; Yap, H.-L.; Yeo, W.-L. ; Soong, R.; Ng, S.-S.; Wang, L.-Z.; Cordero, M.T.; Yong, W.-P. ; Goh, B.-C.; Lee, S.-C. 
15Aug-2011Germline genetic testing to predict drug response and toxicity in oncology- Reality or fiction?Soh, T.I.; Yong, W.P. 
161-Jul-2016High efficacy of BAY 1187982, an FGFR2-ADC, in overcoming drug resistance in a diffuse type gastric cancer patient-derived xenograft model with acquired resistance to pan-FGFR inhibitor AZD4547Lau, Wen Min ; Teng, Eileen ; Huang, Kie Kyon ; Tan, Jin Wei ; Teh, Ming ; Yong, Wei Peng ; Sommer, Anette; Schatz, Christoph A; Tan, Patrick ; Chan, Shing Leng ; So, Jimmy 
17Dec-2010Impact of sample heterogeneity on methylation analysisLoh, M. ; Liem, N.; Lim, P.L.; Vaithilingam, A.; Cheng, C.L.; Salto-Tellez, M. ; Yong, W.P. ; Soong, R. 
18Jan-2013Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancerIvanova, T.; Zouridis, H.; Wu, Y.; Cheng, L.L.; Tan, I.B.; Gopalakrishnan, V.; Ooi, C.H. ; Lee, J.; Qin, L.; Wu, J.; Lee, M.; Rha, S.Y.; Huang, D.; Liem, N.; Yeoh, K.G.; Yong, W.P. ; Teh, B.T.; Tan, P. 
19Aug-2011Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapyTan, I.B.; Ivanova, T.; Lim, K.H.; Ong, C.W. ; Deng, N. ; Lee, J.; Tan, S.H.; Wu, J.; Lee, M.H.; Ooi, C.H. ; Rha, S.Y.; Wong, W.K.; Boussioutas, A.; Yeoh, K.G.; So, J.; Yong, W.P. ; Tsuburaya, A.; Grabsch, H.; Toh, H.C.; Rozen, S. ; Cheong, J.H.; Noh, S.H.; Wan, W.K.; Ajani, J.A.; Lee, J.; Tellez, M.S. ; Tan, P. 
20Apr-2006Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drugTham, L.-S.; Lee, H.-S.; Wang, L. ; Yong, W.-P. ; Fan, L.; Ong, A.-B.; Sukri, N.; Soo, R. ; Lee, S.-C. ; Goh, B.-C.